Male Contraceptives: Why Contraline’s $92.5M Raise Could Reshape the Category

On June 2nd, Contraline announced a $92.5 million Series B financing. While the size of the round is notable, the more meaningful signal comes from who participated.

The financing was co-led by BVF Partners and RA Capital Management, two crossover funds that almost exclusively back therapeutics. Their participation suggests they see more than an interesting technology. They see the potential for an entirely new market with a drug-sized outcome.

Here’s what the numbers reveal.

The Investment Case for Male Contraceptives

The biggest opportunity starts with what is missing.

For decades, men have effectively had only two contraceptive choices: condoms and vasectomy. No new male method has reached the market in a generation.

That helps explain why today’s global male contraceptives market is valued at only about $1.12 billion. The category remains small largely because there are so few products available, not necessarily because demand is limited.

Research suggests the market could look very different if additional options become available. Survey data indicates that more than 7 million U.S. men, or roughly 13%, would adopt a novel contraceptive method, with estimates increasing to approximately 15.5 million under looser assumptions.

Following this financing, Contraline has now raised approximately $127 million in total capital. Much of the new funding is expected to support the company’s late-stage clinical development efforts.

For crossover investors, this combination is unusually attractive: a market with little direct competition, measurable unmet demand, and a clinical program that has advanced far enough to significantly reduce development risk.

Contraline Is Building Two Different Male Contraceptive Approaches

Unlike many companies pursuing a single technology, Contraline has positioned itself across two distinct approaches to male contraception.

Its lead program, ADAM, is a reversible, non-hormonal hydrogel implanted into the vas deferens during an outpatient procedure performed under local anesthesia. The hydrogel temporarily blocks sperm while preserving sensation and ejaculation.

Clinical results helped drive investor confidence. In the company’s first-in-human study, the first two participants to reach the 24-month follow-up achieved azoospermia, reducing sperm counts from an average baseline of 81.5 million/mL to zero, while the 30-participant study reported no serious adverse events. ADAM has since advanced into a Phase II trial.

The company’s second asset provides diversification.

Through an exclusive option-to-license agreement with the Population Council, Contraline holds rights to NES/T, a daily hormonal gel combining Nestorone and testosterone. The program has already completed Phase II evaluation in a 462-couple study.

Together, ADAM and NES/T give Contraline exposure to two of the three major technological approaches currently being pursued across the field.

Three Different Paths Are Emerging

Rather than one technology competing against another, male contraception is increasingly separating into three distinct categories.

The oral approach is represented by YourChoice Therapeutics’ YCT-529, a non-hormonal pill currently in Phase Ib/IIa, with data expected around mid-2026.

The hormonal gel category now includes NES/T under Contraline’s portfolio.

The implant category includes Contraline’s ADAM alongside NEXT Life Sciences’ Plan A, another hydrogel that entered Phase II in October 2025.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/male-contraceptives-why-contralines-925m-raise-could-reshape-the-category